women (80/113) attended for postnatal GTT, and 25% of these (20/80) were abnormal. Macrosomia (defined as birth-weight ≥4000 g) affected 20.3% of babies. One baby required admission to the neonatal unit due to hypoglycaemia.

**Conclusion** In RIE, women with GDM receive appropriate medication. The quality of glycaemic control has been maintained since metformin became the first-line medication. Suboptimal attendance for postnatal GTT must be addressed to optimise the health of these women who are at risk of developing Type 2 diabetes.

**PM09** THE EFFECT OF GLUCOCORTICOIDS ON ANGIogenesis in the human placenta

doi:10.1136/archdischild-2013-303966.094

JC Stratta, V Palin, CP Sibley, P Brownhill, H Bischof, RL Jones. Maternal and Fetal Health Research Centre, The University of Manchester, M13 9WL, Manchester, UK

**Background** Fetal growth restriction (FGR) is associated with glucocorticoid (GC) excess in human pregnancies and animal models. In mice and rats, GC treatment reduces placental angiogenesis and dysregulates the expression of angiogenic factors. It is not known whether GCs reduce angiogenesis in the human placenta.

**Hypothesis** Glucocorticoid excess in the human placenta inhibits angiogenesis by dysregulating angiogenic factors.

**Methods** Human umbilical vein endothelial cells (HUVECs) and human placental artery endothelial cells (HPAECs) were treated with hydrocortisone (HC), prednisolone (PRED) and dexamethasone (DEX) for 24–48 hours. Tube-like structure (TLS) formation on matrigel, cell migration, proliferation and apoptosis were assessed. Chorionic plate arteries (CPAs) from normal placentas (n = 10) were cultured for 48 hours with HC or DEX. mRNA expression of six angiogenic factors were quantified using real-time Q-PCR with normalisation to TBP.

**Results** Pilot studies in HUVECs (n = 3, p < 0.05) and subsequent experiments in HPAECs (n = 7, p = 0.05-0.01) treated with 10–1,000 nM HC, PRED and DEX showed reduced TLS formation and cell migration compared to vehicle control cells. GCs had no effect on cell proliferation, apoptosis or viability. HC and DEX treatment reduced the expression of fibroblast growth factor-2 (FGF-2) (p < 0.001), interleukin-8 (p < 0.001), VEGF-A (p < 0.01), VEGF-C (p < 0.01), matrix metalloproteinase-16 (p < 0.01), matrix metalloproteinase-1 (p < 0.05) and CCL-2 (p < 0.05).

**Discussion** GCs reduced tube formation and cell migration, key facets of angiogenesis, in HUVEC and HPAEC models. These findings indicate that GCs inhibit human placental angiogenesis, which could contribute to the pathogenesis of FGR. The downregulation of specific angiogenic factors by GCs identifies putative mechanistic pathways involved.

**PM10** ARE LOW PAPP-A CONCENTRATIONS ASSOCIATED WITH PLACENTALLY-MEDIATED COMPLICATIONS IN WOMEN WITH ANTIPHOSPHOLIPID SYNDROME (APS)?

doi:10.1136/archdischild-2013-303966.095

MC Soh, C Nelson-Piercy, L Chappell, S Sankaran. Women’s Health Academic Centre, King’s College London, King’s Health Partners, London, UK

Women with antiphospholipid syndrome (APS) have pregnancies complicated by placently-mediated events whereas women with antiphospholipid antibodies (aPL) have similar pregnancy outcomes to the normal population. Low PAPP-A concentrations are useful in predicting adverse pregnancy outcomes in the general population.

We aimed to determine whether PAPP-A concentrations could identify women with APS at risk of adverse outcomes.

**Methods** This retrospective case control study included all women with singleton pregnancies (without fetal anomalies) with persistent aPL and PAPP-A concentrations between 2008 and 2012. The women were grouped as those fulfilling the classification criteria for APS and those who had persistent aPL without a history of thrombosis or adverse pregnancy outcomes. Data obtained included demographic details, medical comorbidities, aPL subtypes, nicotine use. Pregnancy outcomes included live birth, miscarriages > 10 weeks, pre-eclampsia, abortion, birthweight.

**Results** Sixty-one cases were identified. There were no significant differences in maternal baseline characteristics. Live birth rates were similar between both groups. There were significant differences (p < 0.05) between all placentally-mediated complications, birthweight and customised birthweight centiles. However, despite these complications, PAPP-A concentrations were similar. There was no trend towards adverse outcomes with lower PAPP-A concentrations.

**Conclusion** Despite the high rate of placentally-mediated complications in women with APS, a low PAPP-A was not useful in predicting these complications.

**PM11** A LABEL-FREE SRM WORKFLOW IDENTIFIES A SUBSET OF PREGNANCY SPECIFIC GLYCOPROTEINS AS NOVEL PREDICTIVE MARKERS OF EARLY-ONSET PRE-ECLAMPSIA

doi:10.1136/archdischild-2013-303966.096

1RT Blankley, C Fisher, 1M Westwood, 1RA North, 2Baker Philip, 1T Whetton, 3McCowan, 5Deikin, 2R Unwin, 4JE Myers. 1University of Manchester, Manchester, UK; 2University of Auckland, Auckland, New Zealand; 3University of Adelaide, Australia, Australia; 4Kings College London, London, UK

**Objective** The aim of this study was to identify and verify plasma protein markers which may add to predictive algorithms for pre-eclampsia (PE) in asymptomatic nulliparous women.

**Methods** We used a quantitative mass spectrometry (MS) approach to identify proteins with abundance changes in plasma (15 weeks) taken from women who subsequently develop PE recruited to the international SCOPE study. We developed a novel, targeted, label-free MS method, selective reaction monitoring (SRM) which enabled robust and reproducible verification of these proteins in a further 100 samples (16 early-onset PE, 42 late-onset PE, 42 controls).

**Results** We identified and quantified >500 plasma proteins, and prioritised a set of candidate predictive markers. The two most promising, Platelet Basic Protein (PBP/NAP-2) and Pregnancy-specific glycoprotein (PSG)-9 were selected for further verification. The SRM method was validated extensively using dilution experiments for PSG proteins and by comparison to a commercial ELISA for NAP-2. NAP-2 was only elevated in a subset of women with PE, however, peptides unique to PSG-9 and PSG-5 were consistently elevated in women with subsequent early onset PE (p < 0.01; AUCs 0.72–0.75). Other PSG peptides were not different between groups.

**Conclusion** This study has identified specific PSG proteins as being predictive of early-onset PE. Importantly, use of a highly specific MS method has enabled measurement of individual PSG family members which has not been possible using antibody-based techniques. Future work is needed to determine whether these proteins will improve current prediction algorithms for the identification of PE in low risk nulliparous women.